The FUTURE-AI guidelines have been developed with the aim of improving the reliability, safety, and ethical aspects of artificial intelligence (AI) in healthcare. Although AI has revolutionized disease diagnosis and treatment prediction, many doctors and patients are wary of its use, mainly due to fears of bias, errors, and data privacy risks. To counter these, the FUTURE-AI Consortium of 117 experts from 50 countries has developed a set of recommendations that have been published in *BMJ*.
The FDA has issued a clinical hold on Amgen’s phase I trial of the experimental weight-loss drug AMG 513. In other news, Children’s Hospital Los Angeles has suspended the initiation of puberty blockers in transgender patients younger than 19 after an executive order from former President Trump. Defense Secretary Pete Hegseth has also directed the military to suspend the integration of new transgender recruits and to suspend medical treatment for troops with gender dysphoria.
The study can provide useful information to interventional cardiologists performing PCI with new-generation DES in AMI patients, regarding the importance of hyperglycemia (especially prediabetes) and the relationship with worse cardiovascular outcomes after both high intensity and low-moderate-intensity statin treatment
